Oak Ridge Investments LLC Sells 1,808 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Oak Ridge Investments LLC lowered its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 5.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,926 shares of the biotechnology company’s stock after selling 1,808 shares during the quarter. Oak Ridge Investments LLC’s holdings in Arrowhead Pharmaceuticals were worth $504,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after purchasing an additional 1,018,273 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after purchasing an additional 2,774,933 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Arrowhead Pharmaceuticals by 0.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company’s stock valued at $32,220,000 after purchasing an additional 21,686 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after purchasing an additional 447,456 shares in the last quarter. Finally, Aberdeen Group plc boosted its position in Arrowhead Pharmaceuticals by 138.4% during the first quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company’s stock valued at $13,668,000 after purchasing an additional 622,752 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ:ARWR opened at $35.41 on Monday. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $39.42. The stock has a market cap of $4.90 billion, a price-to-earnings ratio of -27.66 and a beta of 1.13. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average price of $26.59 and a 200-day moving average price of $18.98.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analysts’ expectations of $29.01 million. During the same period last year, the firm posted ($1.38) EPS. Equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Royal Bank Of Canada decreased their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Wall Street Zen cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 18th. TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. Finally, B. Riley upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.14.

Insider Activity

In related news, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider directly owned 212,122 shares in the company, valued at approximately $7,424,270. This trade represents a 8.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 60,000 shares of company stock valued at $1,725,000 in the last three months. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.